GSK2586184: Development discontinued
Galapagos disclosed in its 2Q14 earnings that partner GlaxoSmithKline completed an assessment of the overall benefit-risk profile of GSK2586184 and decided to discontinued development of the compound for all current indications - SLE, UC and psoriasis. According to Galapagos, GSK decided to discontinue the UC and psoriasis indications “principally as a result of the statin drug-drug interaction (DDI) study.” GSK said data are not yet disclosed and added that it is exploring development options for the compound in other indications.
In February, GSK discontinued due to “lack of effect” a Phase II trial evaluating GSK2586184 to treat SLE after the first planned interim analysis met undisclosed pre-defined stopping criteria. At the same time, the pharma also placed an open-label Phase I/II trial of GSK2586184 for UC on hold (see BioCentury, March 3). In April, top-line data showed that GSK2586184 met the primary endpoint in the Phase IIa JAK116679 trial to treat chronic plaque psoriasis (see BioCentury, April 21). ...